Preclinical Alzheimer's disease

There are 214 papers on preclinical Alzheimer's disease in aging research: 2 trials and 184 observational studies in people, 19 reviews. The newest story, Oct 26, 2026: “Anxiety linked to Alzheimer’s-related brain changes”.

Disease

214 papers study it272 more mention it55 findings

19 new papers in 30 daysSee all 486 papers on preclinical Alzheimer's disease

At a glance

Preclinical Alzheimer's disease is associated with poorer cognition in cognitively normal older adults and altered brain connectivity in human studies. Plasma GFAP, rest–activity fragmentation and dual-task performance are also associated with disease status. Brain atrophy results differ across studies, including a study finding no clear link when age ranges are matched.

55 findings in 41 papers from 2015 to 2026, 3 of them since April 2026

“Both participant and study partner CFI increased over the duration of the study indicating worsening cognitive functioning. Results did not differ by treatment group.”
Longitudinal Trajectories of the Cognitive Function Index in the A4 StudyThe journal of prevention of Alzheimer's disease2024doi:10.14283/jpad.2024.125
  • Human trial2
  • Humans184
  • In silico7

Effects

22

Resistin

no changein humans1upin humans1

1 study
  1. Preclinical Alzheimer's disease was not clearly linked with resistin in preclinical AD vs controls.

    Humansin preclinical AD vs controlsplasmafemalesn = 91

  2. Preclinical Alzheimer's disease is linked with higher resistin in preclinical AD vs controls.

    Humansin preclinical AD vs controlsplasmamalesn = 64

More on Resistin

Driving reaction time

no changein humans1upin humans1

1 study
  1. Preclinical Alzheimer's disease showed no clear effect on driving reaction time in humans (when a distraction was added).

    Human trialwhen a distraction was added

  2. Preclinical Alzheimer's disease increases driving reaction time in humans (without distracters) (7.56 ± 1.46 s vs 6.42 ± 1.17 s, p = .02).

    Human trialwithout distracters

Cognitive function

downin humans1

1 study
  1. Preclinical Alzheimer's disease is linked with lower cognitive function in humans (removing PCAD participants from normative sample).

    Humansremoving PCAD participants from normative samplen = 264

  2. Preclinical Alzheimer's disease is linked with worse cognitive function in cognitively normal older adults.

    Humansin cognitively normal older adultsn = 264

Resting-state functional connectivity

downin humans1

1 study
  1. Preclinical Alzheimer's disease is linked with worse resting-state functional connectivity in humans (preclinical AD (Aβ+)).

    Humanspreclinical AD (Aβ+)n = 151

Functional connectivity between default mode network and other networks

downin humans1

1 study
  1. Preclinical Alzheimer's disease is linked with lower functional connectivity between default mode network and other networks in humans (preclinical Alzheimer's disease (Aβ+ CN)).

    Humanspreclinical Alzheimer's disease (Aβ+ CN)brainn = 396

Functional connectivity within default mode network

upin humans1

1 study
  1. Preclinical Alzheimer's disease is linked with higher functional connectivity within default mode network in humans (preclinical Alzheimer's disease (Aβ+ CN)).

    Humanspreclinical Alzheimer's disease (Aβ+ CN)brainn = 396

Cognivue Clarity global score

downin humans1

1 study
  1. Preclinical Alzheimer's disease is linked with worse Cognivue Clarity global score in humans (compared to True Controls) (p <.001).

    Humanscompared to True Controls

More on Cognivue Clarity global score

Learning over consecutive days

downin humans1

1 study
  1. Preclinical Alzheimer's disease impairs learning over consecutive days in biomarker‐positive participants.

    Reviewin biomarker‐positive participants

Interhemispheric functional connectivity difference

upin humans1

1 study
  1. Preclinical Alzheimer's disease is linked with higher interhemispheric functional connectivity difference in humans (between the first and second verbal trials).

    Humansbetween the first and second verbal trialsprefrontal cortex

More on Interhemispheric functional connectivity difference

Interhemispheric functional connectivity

upin humans1

1 study
  1. Preclinical Alzheimer's disease is linked with higher interhemispheric functional connectivity in humans during verbal tasks involving the first phonemic letter.

    Humansduring verbal tasks involving the first phonemic letterprefrontal cortex

More on Interhemispheric functional connectivity

Cognitive Function Index

upin humans1

1 study
  1. Preclinical Alzheimer's disease increases Cognitive Function Index in humans (preclinical Alzheimer's disease).

    Human trialpreclinical Alzheimer's disease240 weeksn = 1,147

More on Cognitive Function Index

All 22

Associations

28

GFAP

upin humans2

2 studies
  1. Preclinical Alzheimer's disease is associated with GFAP in humans (Preclinical Alzheimer's disease compared with healthy elderly).

    HumansPreclinical Alzheimer's disease compared with healthy elderlyplasman = 100

  2. GFAP predicts preclinical Alzheimer's disease in humans (base model combined with GFAP in preclinical AD) (>90%).

    Humansbase model combined with GFAP in preclinical AD

More on GFAP

Dual-task cost

upin humans1

1 study
  1. Dual-task cost is associated with preclinical Alzheimer's disease in humans (aOR 1.16, 95% CI 1.02-1.32).

    Humans20-unit increase in DTCn = 203

  2. Preclinical Alzheimer's disease is associated with dual-task cost in humans (dual task balance condition) (mean difference 19.8, 95% CI 2.6-37.0, p = .024).

    Humansdual task balance conditionn = 203

More on Dual-task cost

GFAP and NfL

upin humans1

1 study
  1. Preclinical Alzheimer's disease is associated with GFAP and NfL in humans.

    HumansBiomarker-defined preclinical Alzheimer's disease with intact cognition and medically managed risk factorsn = 93

    Alzheimer's marker linked to subtle differences in older adults

    bioRxivPreprint

More on GFAP and NfL

Physiological measures

mixedin humans1

1 study
  1. Preclinical Alzheimer's disease is associated with physiological measures in humans.

    HumansBiomarker-defined preclinical Alzheimer's disease with intact cognition and medically managed risk factorsn = 93

    Alzheimer's marker linked to subtle differences in older adults

    bioRxivPreprint

Cognitive and behavioral phenotype

mixedin humans1

1 study
  1. Preclinical Alzheimer's disease is associated with cognitive and behavioral phenotype in humans.

    HumansBiomarker-defined preclinical Alzheimer's disease with intact cognition and medically managed risk factorsn = 93

    Alzheimer's marker linked to subtle differences in older adults

    bioRxivPreprint

p-Tau217

upin humans1

1 study
  1. p-Tau217 is associated with preclinical Alzheimer's disease in humans (preclinical AD Biological Stage A).

    Humanspreclinical AD Biological Stage An = 222

More on p-Tau217

Cortical Aβ-myelin coupling

mixedin humans1

1 study
  1. Preclinical Alzheimer's disease is associated with cortical Aβ-myelin coupling in humans (preclinical AD (Aβ+)).

    Humanspreclinical AD (Aβ+)n = 151

More on Cortical Aβ-myelin coupling

Clinical trial eligibility

upin silico1+5.5%

1 study
  1. Preclinical Alzheimer's disease is associated with clinical trial eligibility in silico with preAD and SCD symptoms (5.5%).

    In silicowith preAD and SCD symptoms

Subjective cognitive decline

upin silico1

1 study
  1. Subjective cognitive decline is associated with preclinical Alzheimer's disease in silico with subjective cognitive decline (approximately 8.4 million).

    In silicowith subjective cognitive decline

Driving features

upin humans1

1 study
  1. Driving features predict preclinical Alzheimer's disease in humans (AUC 0.84, accuracy 0.85, F1 0.85).

    Humansn = 254

More on Driving features

All 28

Trial sponsors

Funding

69 grants since 2016

National Institute on Aging$118MUS Department of Veterans AffairsAlzheimer's Association

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 75Jan 2026: 15Feb 2026: 9Mar 2026: 6Apr 2026: 14May 2026: 7Jun 2026: 11Jul 2026: 6Aug 2026: 7Sep 2026: 3Oct 2026: 16Nov 2026: 11180 papers in 12 months
bioRxiv

Anxiety linked to Alzheimer’s-related brain changes

Among 1,775 older adults without cognitive impairment, anxiety-related and Alzheimer’s-related brain networks resembled each other, with a correlation of 0.74.Among 1,775 older adults without cognitive impairment, anxiety-related and Alzheimer’s-related brain networks resembled each other, with a correlation of 0.74.

Preprint: cross-sectional · 1,775 peoplePreclinical Alzheimer's disease
JAMA Neurology

Alzheimer’s blood marker varied by race and ethnicity

A cross-sectional analysis of 15,612 adults aged 55–80 screened for Alzheimer’s trials found blood marker differences between racial and ethnic groups.A cross-sectional analysis of 15,612 adults aged 55–80 screened for Alzheimer’s trials found blood marker differences between racial and ethnic groups.

Cross-sectional study of 15,612 peoplePreclinical Alzheimer's disease
Alzheimer's & Dementia

Combined test scores predicted later thinking problems

An overall thinking score matched an established measure in classifying progression to mild cognitive impairment, with a performance score of 0.70.An overall thinking score matched an established measure in classifying progression to mild cognitive impairment, with a performance score of 0.70.

Cohort study of 1,964 peopleBiomarkers

See all 486 papers on preclinical Alzheimer's disease